Skip to main content
. Author manuscript; available in PMC: 2008 Oct 6.
Published in final edited form as: J Thorac Oncol. 2008 Sep;3(9):1018–1025. doi: 10.1097/JTO.0b013e3181834fa1

Table 4.

Efficacy.

Variable Phase I Phase II
Best response
  Evaluable 8 25
  Complete response 0 0
  Partial response 1 1
  Stable disease 3 12
  Progressive disease 4 12
TTP and Survival
  Evaluable 30 30
  Median TTP, months 4.2 (95% CI: 1.9 – ∞) 4.7 (95% CI: 3.1 – 9.3)
  Median OS, months 11.6 (95% CI: 6.0 – 52) 9.6 (95% CI: 6.6 – 19.1)
  1-year survival, percent 50 (30% standard error) 47 (9% standard error)

Abbreviations: TTP, time-to-progression; OS, overall survival; CI, confidence interval.